Clinical trial
Cystic Fibrosis: Implications for Vascular Health and Function
NCT07904325 is registered in ClinicalTrials.gov with Liverpool Heart and Chest Hospital NHS Foundation Trust as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Cystic Fibrosis: Implications for Vascular Health and Function
- Lead sponsor
- Liverpool Heart and Chest Hospital NHS Foundation Trust
- Phase
- Observational
- Overall status
- Not yet recruiting
- Start date
- October 10, 2026
- Completion date
- July 1, 2030
- Enrollment
- 100 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
cardiovascular risk factor, cystic fibrosis, endothelial dysfunction
Arms
As registered; 2 arms.
-
Adults with cystic fibrosis
Adults aged 40 years or older with a confirmed diagnosis of cystic fibrosis, receiving CFTR modulator therapy at a recognised therapeutic dose and clinically stable (no pulmonary exacerbation or hospitalisation in the previous 4 weeks), recruited consecutively from the adult CF outpatient clinics at Liverpool Heart and Chest Hospital. Target n = 50. Participants attend a single study visit for vascular, cerebrovascular, autonomic, blood, cognitive and questionnaire assessments.
-
Healthy controls
Healthy adults aged 40 years or older, matched to participants with CF for sex and age (within 4 years), in sinus rhythm with normal blood pressure (below 140/90 mmHg) and taking no prescription medications other than contraceptives or hormone replacement therapy. Recruited from the local community (including NHS and university staff and students) via advertisements. Target n = 50. Participants attend a single study visit at Liverpool Heart and Chest Hospital or Manchester Metropolitan University for the same assessments as the CF group.
Primary endpoints
Registered primary outcome measures; 2 primary.
-
Radial artery flow-mediated dilation (FMD)
Percentage change in radial artery diameter
-
Radial artery low-flow mediated constriction (L-FMC)
Percentage change in radial artery diameter
Lead sponsor's other trials
Liverpool Heart and Chest Hospital NHS Foundation Trust, most recent start first.
+27 more trials See the organization page
Similar trials
Same condition (Cystic Fibrosis) and phase, most recent start first.
+499 more trials See the condition page